bluebird bio Inc.

bluebird bio Inc.
Stock Exchange Frankfurt Stock Exchange
EPS
-
Market Cap
-
Shares Outstanding
54.16 M
Public Float
31.37 M
bluebird bio Inc.
Stock Exchange NASDAQ Stock Market
EPS
$11.36
Market Cap
$7.05 B
Shares Outstanding
55.12 M
Public Float
54.5 M

Profile

Address
60 Binney Street
Cambridge Massachusetts 02142
United States
Employees -
Website http://www.bluebirdbio.com
Updated 07/08/2019
bluebird bio, Inc. is a clinical-stage biotechnology company. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. It offers the LentiGlobin which is a treatment for transfusion-dependent ß-thalassemia; and Lenti-D as a treatment for cerebral adrenoleukodystrophy.

Financials

View All

Nick Leschly
President, Chief Executive Officer & Director
Daniel S. Lynch
Chairman